Added value and clinical impact of second-opinion subspecialist radiologist interpretations of baseline rectal MRI in patients with rectal cancer
- PMID: 41236658
- PMCID: PMC12895060
- DOI: 10.1007/s00330-025-12132-9
Added value and clinical impact of second-opinion subspecialist radiologist interpretations of baseline rectal MRI in patients with rectal cancer
Abstract
Objectives: To evaluate the completeness and discordance of outside rectal MRI initial staging reports compared to second-opinion reviews, and to assess the potential clinical impact of major discordance on treatment decisions in patients with rectal adenocarcinoma.
Materials and methods: A retrospective analysis of outside rectal MRI reviews submitted for second-opinion interpretation by subspecialized radiologists from June 2014-March 2020 was conducted. Outside and second review reports were compared side-by-side; cases with discordance (and those with major discordance, i.e., may alter treatment, particularly) were identified. Two colorectal surgeons, blinded to report origins, reviewed cases with major discordance to evaluate their theoretical impact on patient management and rated their confidence level of the reports on a five-point Likert scale (1=lowest confidence).
Results: In 461 patients (median age, 57 years [IQR: 49-67]; 274 male), compared to outside reviews, second reviews demonstrated improved report completeness across tumor characteristics, local extent, and nodal/metastatic disease clinical staging categories. The largest reporting gaps were in tumor morphology (66.4%, 306/461 vs. 98.7%, 455/461) and extramural venous invasion (29.1%, 134/461 vs. 93.9%, 433/461). Overall, 53.8% (248/461) of cases showed discordance, with 56.5% (140/248) classified as major. In this subset, second reviews led to fewer cases with insufficient information, e.g., 18.6% (26/140) to 7.1% (10/140) for Surgeon 1, and changes in surgical planning in 38.1-46.3% (43/113 to 44/95) of patients. Surgeons rated reports from second reviews with higher confidence scores (median, 4 vs. 2-3, p < 0.001).
Conclusions: Second-opinion reviews may impact patient care and improve surgeons' confidence for treatment planning.
Key points: Question Do subspecialist radiologist second-opinion reviews improve rectal MRI report completeness and affect treatment decisions in rectal adenocarcinoma staging? Findings While outside reviews often under-reported key imaging findings, second reviews improved report completeness, which led to increased confidence by our surgeons in treatment planning. Clinical relevance These findings underscore the value of expert interpretation and highlight the need for optimized MRI protocols and broader adoption of structured reporting in rectal cancer staging.
Keywords: Rectal adenocarcinoma; Rectal neoplasms; Second-opinion; Treatment planning; Tumor staging.
© 2025. The Author(s), under exclusive licence to European Society of Radiology.
Conflict of interest statement
Compliance with ethical standards. Guarantor: The scientific guarantor of this publication is Jennifer S. Golia Pernicka, MD, from Memorial Sloan Kettering Cancer Center. Conflict of interest: The authors of this manuscript declare relationships with the following companies: Dr. Natally Horvat received lecture honoraria from Bayer (September 2022) and from Guerbet (May 2024). Dr. Horvat also served as a clinical consultant advisor for Guerbet (February 2023), received travel support from Guerbet (February 2023 and May 2024) and received writing support from Guerbet (March 2025). The remaining authors declare no conflict of interest. Statistics and biometry: One of the authors, Stephanie Nougaret, MD, PhD, from the Montpellier Cancer Institute, Montpellier, France, has significant statistical expertise. Informed consent: Written informed consent was waived by the Institutional Review Board. Ethical approval: Institutional Review Board approval was obtained from Memorial Sloan Kettering Cancer Center. Study subjects or cohorts overlap: None. Methodology: Retrospective Observational Performed at one institution
Figures
References
-
- Conroy T, Bosset JF, Etienne PL et al. (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702–715 - PubMed
-
- Bahadoer RR, Dijkstra EA, van Etten B et al. (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29–42 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
